All In Biotech

Free tool

FAERS Monitor: Zinc Sulfate

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209377 or its brand name (Zinc Sulfate, Zinc Sulfate). Reports on generic versions are filed under their own applications.

Reports

2,864

Serious

2,169

76% of reports

Hospitalization

1,285

Death reported

396

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea226
  • fatigue185
  • nausea177
  • off label use158
  • death156
  • pain147
  • vomiting145
  • dyspnoea140
  • pyrexia131
  • headache111
  • asthenia103
  • pneumonia101
  • back pain96
  • anaemia95
  • drug ineffective94

Reports by year received

View as table
YearReports
200448
200520
200625
200726
200821
200945
201044
201148
2012225
201344
201463
201592
2016156
2017114
2018152
2019158
2020373
2021231
2022262
2023193
2024163
2025210
2026151

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,295 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
anaemiaSignal953.73.0183
back painSignal963.02.5130
pyrexiaSignal1312.82.4150
diarrhoeaSignal2262.62.3222
pneumoniaSignal1012.31.973
vomitingSignal1452.31.9103
astheniaSignal1032.01.752
dyspnoea1401.81.552
pain1471.81.549
fatigue1851.71.560
nausea1771.61.446
death1561.31.113
off label use1581.31.113
headache1111.31.18
drug ineffective940.50.443

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.